Anavex Life Sciences Corp. (AVXL) Earnings History
Annual and quarterly earnings data from 2004 to 2025
Loading earnings history...
AVXL EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
AVXL Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
Download Data
Export AVXL earnings history in CSV or JSON format
Free sign-in required to download data
Anavex Life Sciences Corp. (AVXL) Earnings Overview
As of May 7, 2026, Anavex Life Sciences Corp. (AVXL) reported trailing twelve-month net income of -$40M, reflecting -3.8% year-over-year growth. The company earned $-0.45 per diluted share over the past four quarters.
Looking at the long-term picture, AVXL's historical earnings data spans multiple years. The company achieved its highest annual net income of -$14,395 in fiscal 2004.
Anavex Life Sciences Corp. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including SAVA (-$106M net income), PRAX (-$303M net income), ACAD ($391M net income, 36.5% margin), AVXL has comparable earnings metrics. Compare AVXL vs SAVA →
AVXL Earnings vs Peers
Earnings metrics vs comparable public companies
AVXL Historical Earnings Data (2004–2025)
22 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$46M | -7.8% | -$51M | $-0.54 | - | - |
| 2024 | -$43M | +9.5% | -$53M | $-0.52 | - | - |
| 2023 | -$48M | +1.0% | -$56M | $-0.60 | - | - |
| 2022 | -$48M | -26.6% | -$51M | $-0.62 | - | - |
| 2021 | -$38M | -44.3% | -$42M | $-0.54 | - | - |
| 2020 | -$26M | +0.1% | -$31M | $-0.45 | - | - |
| 2019 | -$26M | -50.7% | -$29M | $-0.54 | - | - |
| 2018 | -$17M | -29.7% | -$19M | $-0.39 | - | - |
| 2017 | -$13M | +8.7% | -$16M | $-0.33 | - | - |
| 2016 | -$15M | -21.7% | -$16M | $-0.42 | - | - |
See AVXL's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs AVXL Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare AVXL vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonAVXL — Frequently Asked Questions
Quick answers to the most common questions about buying AVXL stock.
Is AVXL growing earnings?
AVXL EPS of $-0.45 reflects slowing growth at -3.8%, below the 5-year CAGR of N/A. TTM net income is $-40M. Expansion rate has moderated.
What are AVXL's profit margins?
Anavex Life Sciences Corp. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are AVXL's earnings?
AVXL earnings data spans 2004-2025. The current earnings trend is -3.8% YoY. Historical data enables comparison across business cycles.